RxSight shareholders re-elect three Class III directors, approve say-on-pay, one-year frequency, and E&Y ratification

RxSight, Inc.

Three Class III directors re-elected: Julie B. Andrews, Robert J. Palmisano, Tamara R. Fountain.
Say-on-pay approved: 22.6M for, 1.1M against, 0.4M abstain.
Advisory vote on frequency: one-year option favored with 20.5M votes; company will hold annual say-on-pay.
Ratification of Ernst & Young as independent auditor for FY 2024: 29.9M for, 46k against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.